Since sustained virologic remission of HBV does not occur as a result of existing treatment, novel strategies will have to be adopted. A learned approach to achieve this goal is to circumvent the various factors by which HBV establishes chronic infection in humans. Targeting a combination of viral and host factor offers the best possible chance for accomplishing this objective. Safety of a variety of these approaches, especially those targeting host immune responses have not yet been established. If these approaches are safe, they offer a unique perspective to target host immunity against HBV proteins and eventually develop protective immunity and control of HBV replication. A key viral target remains cccDNA, which requires unique approaches, which have shown in vitro effectiveness. The challenges remain on developing successful delivery system that allows every single infected cell to be subjected to disruption of ccDNA. In reality, a combination approach would be the most appropriate, effective and pragmatic technique to achieve sustained virologic remission of most CHB patients (Figure 1 & Table 1 & Table 2).作者: newchinabok 时间: 2014-10-7 15:54